Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
441 employees
NYC-based Owkin, Inc. leverages machine learning for predictive analytics in biotech, serving global pharma.
HQ
Founded
2016
Founded in New York City, Owkin, Inc. is a biotech company specializing in predictive analytics through machine learning. Its core mission is to revolutionize drug discovery and development by analyzing complex biomarker patterns in molecular, imaging libraries, and patient datasets. Owkin offers services such as AI-driven drug discovery, target discovery, and diagnostics, focusing on serving pharmaceutical companies globally. Their vision is to harness the power of AI to uncover insights that can lead to more effective treatments and improved patient outcomes.
Notable affiliated people include co-founders Thomas Clozel and Gilles Wainrib. Owkin has attracted significant investment from major players like GV (formerly Google Ventures) and Bpifrance. Key achievements include developing a federated research network that allows secure, collaborative data analysis across institutions without sharing sensitive data. Owkin's impact is evident in its contributions to advancing precision medicine and enhancing the efficiency of pharmaceutical research and development.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Diagnostics, AI Drug Discovery
Technology
AI, Machine Learning
Tags
Biotech, Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Owkin founded?
Owkin was founded in 2016.
Where is Owkin's headquarters located?
Owkin's headquarters is located in New York City, NY, US.
When was Owkin's last funding round?
Owkin's most recent funding round was for $50M (USD) in June 2022.
How many employees does Owkin have?
Owkin has 441 employees as of Feb 4, 2024.
How much has Owkin raised to-date?
As of July 05, 2023, Owkin has raised a total of $304.1M (USD) since Jun 8, 2022.
Add Comparison
Total Raised to Date
$304.1M
USD
Last Update Jun 8, 2022
Last Deal Details
$50M
USD
Jun 8, 2022
Series B
Current Employees
441
Last updated: Feb 4, 2024
No location information available for this company.
Locations
TechCrunch
Altrove uses AI models and lab automation to create new materials
For the past couple of years, innovation has been accelerating in new materials development. And a new French startup called Altrove plans...
Jul 3, 2024
Is this the right Owkin?
Help us improve our AI - Is this article for the right company?
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts